| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-9149(96)00742-4 |
| P698 | PubMed publication ID | 9024733 |
| P2093 | author name string | D B Hunninghake | |
| S R Weiss | |||
| E A Stein | |||
| R H Knopp | |||
| D R Illingworth | |||
| M H Davidson | |||
| M R Melino | |||
| Y B Mitchel | |||
| J A Tobert | |||
| M R Dobrinska | |||
| C A Dujovne | |||
| R V Zupkis | |||
| R D Amin | |||
| P2860 | cites work | Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent | Q24613185 |
| Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor | Q34310560 | ||
| Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations | Q35180196 | ||
| Cholesterol reduction yields clinical benefit. A new look at old data | Q36697948 | ||
| By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? | Q36884264 | ||
| Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal | Q41036925 | ||
| Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins | Q68129243 | ||
| Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort | Q71431557 | ||
| Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study | Q71664201 | ||
| Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin | Q72728168 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | simvastatin | Q670131 |
| P304 | page(s) | 38-42 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | American Journal of Cardiology | Q2208417 |
| P1476 | title | The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day | |
| P478 | volume | 79 |
| Q77733103 | A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia |
| Q38895987 | A systematic review of interventions to improve adherence to statin medication: What do we know about what works? |
| Q34058386 | Adenosine and cardioprotection during ischaemia and reperfusion--an overview |
| Q44621113 | Atorvastatin Treatment Does Not Affect Gonadal and Adrenal Hormones in Type 2 Diabetes Patients with Mild to Moderate Hypercholesterolemia |
| Q42395227 | Atorvastatin or transgenic expression of TFPI inhibits coagulation initiated by anti-nonGal IgG binding to porcine aortic endothelial cells |
| Q41454232 | Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias |
| Q26853571 | Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes |
| Q34093408 | Clinically relevant differences between the statins: implications for therapeutic selection |
| Q35134264 | Combination lipid-lowering therapy in diabetes |
| Q44239880 | Combination therapy for dyslipidemia: safety and regulatory considerations |
| Q74520839 | Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia |
| Q74556202 | Conversion from fluvastatin to simvastatin therapy at a dose ratio of 8 to 1: effect on serum lipid levels and cost |
| Q47764135 | Current thinking in lipid lowering |
| Q36325378 | Differential associations of plasma lipids with incident dementia and dementia subtypes in the 3C Study: A longitudinal, population-based prospective cohort study |
| Q33786019 | Drug interactions and the statins. |
| Q43518070 | Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia |
| Q34757699 | Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? |
| Q74182384 | Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia |
| Q24650533 | Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit |
| Q29617910 | Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials |
| Q47671221 | Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group |
| Q42545652 | Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia |
| Q28481360 | Exploration of the association rules mining technique for the signal detection of adverse drug events in spontaneous reporting systems |
| Q77309925 | Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor |
| Q33956728 | HMG-CoA reductase inhibitors and myotoxicity |
| Q42544275 | Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin |
| Q38874111 | Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine. |
| Q73887951 | Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy |
| Q73110385 | Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs |
| Q34027319 | Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease |
| Q85678153 | Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial |
| Q24569666 | Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial |
| Q73459941 | Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group |
| Q77569194 | Low-density lipoproteins and risk for coronary artery disease |
| Q34478635 | Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? |
| Q34109455 | New statins and new doses of older statins |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q42688670 | Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist |
| Q33584131 | Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease |
| Q39246204 | Regulation of human platelet aggregation by genetically modified pig endothelial cells and thrombin inhibition |
| Q37693135 | Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. |
| Q41731956 | Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia |
| Q42653850 | STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to Target |
| Q44264686 | Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice |
| Q33876942 | Statins: effective antiatherosclerotic therapy |
| Q28361017 | The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects |
| Q38794761 | The efficacy of evolocumab in the management of hyperlipidemia: a systematic review |
| Q77352978 | The outcome of very low dosages of simvastatin in patients with hypercholesterolemia |
| Q41732385 | Use of cholesterol-lowering medications in the United States from 1991 to 1997. |
Search more.